Southlake, TX, May 08, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq:HSCS) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that it will host a live investor webinar on Wednesday, May 14, 2025, at 2:00 p.m. EDT | 11:00 a.m. PDT, featuring a presentation and Q&A session with CEO Andrew Simpson. Register Now To attend the webinar and participat ...

Core Viewpoint - OpenEvidence is positioned as a leading AI diagnostic tool in the medical field, addressing the challenges of information overload and the rapid growth of medical knowledge, thereby enhancing diagnostic efficiency and decision-making quality for physicians [4][10][11]. Group 1: Background - The medical field faces unprecedented challenges due to the explosive growth of medical knowledge, with literature increasing at a rate of one article every two minutes, leading to significant information overload for doctors [9][10]. - The World Health Organization reports that doctors in low-income countries access cutting-edge medical evidence only 1/9 as frequently as those in high-income countries, highlighting a significant "cognitive gap" [10]. - The aging population and the prevalence of complex cases further complicate clinical decision-making, with traditional guidelines covering less than 7% of scenarios involving polypharmacy [10][11]. Group 2: Product and Technology - OpenEvidence is a chatbot designed to assist medical professionals by providing efficient and accurate clinical support, featuring a unique interface that ensures traceability and verification of information [12][13]. - The product offers dual modes of response: "care guidelines" and "clinical evidence," catering to practical advice and theoretical data support [12]. - OpenEvidence has demonstrated high reliability, scoring over 90% on the USMLE, significantly outperforming general AI models like ChatGPT [16][19]. Group 3: Commercialization and Competition - OpenEvidence employs a direct-to-user growth strategy, bypassing traditional procurement processes in healthcare, which often take years [21][22]. - The company has achieved rapid growth, reaching approximately 100,000 monthly users within a year, covering 10%-25% of practicing physicians in the U.S. [22][23]. - OpenEvidence's business model focuses on targeted advertising, integrating ads from pharmaceutical and medical device companies into the clinical decision-making process [25][26]. Group 4: Team and Financing - The founder, Daniel Nadler, has a strong academic background in economics and AI, with previous successful ventures in the AI space [30][34]. - OpenEvidence secured $75 million in Series A funding from Sequoia Capital in February 2025, achieving a post-money valuation exceeding $1 billion [36].

Core Insights - QIAGEN N.V. reported first-quarter 2025 adjusted earnings per share (EPS) of 55 cents, a 17% increase year-over-year, surpassing the Zacks Consensus Estimate by 10% [1][2] - The company’s net sales for the quarter were $483.5 million, reflecting a 5.4% increase from the previous year and exceeding the Zacks Consensus Estimate by 4.8% [3] Revenue Breakdown - Sample technologies revenues decreased by 3% to $150 million, while diagnostic solutions revenues increased by 9% to $187 million, driven by strong demand for QuantiFERON and QIAstat-Dx [4] - PCR/Nucleic acid amplification revenues rose by 13% to $76 million, and other revenues surged by 57% to $18 million [5] Operational Performance - The adjusted gross profit increased by 4.9% to $322.2 million, with a gross margin of 66.6%, down 29 basis points year-over-year [6] - Adjusted operating income grew by 20% to $140.4 million, with an operating margin expansion of 354 basis points to 29% [7] Financial Position - QIAGEN ended the first quarter with cash and short-term investments totaling $963.4 million, down from $1.20 billion at the end of the previous quarter [9] - The company reported long-term debt of $1.35 billion, slightly up from $1.34 billion in the prior quarter [10] Outlook - For 2025, QIAGEN expects net sales to increase by about 4% at constant exchange rates, with adjusted EPS projected at $2.35 [11] - The company anticipates second-quarter net sales to rise by approximately 5% at constant exchange rates, with adjusted EPS expected to be at least 60 cents [12] Overall Assessment - QIAGEN's first-quarter results indicate a resilient portfolio with strong recurring revenues, despite challenges in gross margins and rising costs [13][15] - The diagnostic solutions segment showed the highest growth, supported by the adoption of new technologies [14]

Core Viewpoint - Lifeward Ltd. is set to release its first quarter 2025 financial results on May 15, 2025, before market opening, indicating a focus on transparency and communication with investors [1]. Company Overview - Lifeward is a global leader in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities [1]. - The company designs, develops, and commercializes solutions that provide functional and health benefits across various care settings, including clinical environments and home care [3]. - Lifeward's product portfolio includes notable innovations such as the ReWalk Exoskeleton, AlterG Anti-Gravity system, MyoCycle FES System, and ReStore Exo-Suit, showcasing its commitment to driving innovation in rehabilitation [3]. Financial Communication - The CEO Larry Jasinski and CFO Mike Lawless will host a conference call and live webcast on May 15, 2025, at 8:30 a.m. EDT to discuss the financial results, emphasizing the company's commitment to engaging with analysts and investors [2]. - Access to the conference call will be available through multiple channels, including toll-free numbers for various regions and a live webcast on the company's website [2].

Group 1 - The article highlights the focus on Omnicell, Inc. (OMCL), a small-cap medical technology solutions provider, which recently reported its Q1 results [2] - The Biotech Forum community discusses lucrative buy-write or covered call opportunities on selected biotech stocks, indicating a trend in investment strategies within the biotech sector [1] - The investing group led by Bret offers a model portfolio featuring 12-20 high upside biotech stocks, along with live chat discussions and weekly research updates [2]

Core Insights - Medtronic's "Letter to My Mother" campaign aims to raise awareness about heart health among women, particularly focusing on the importance of discussing family health history and risk factors [4][13] - A survey conducted by Medtronic reveals a significant gap in awareness and discussions about heart health among women aged 30-50, despite cardiovascular disease being the leading cause of death for women in the U.S. [1][3] Survey Findings - Nearly half of the women (45%) are more likely to discuss sensitive topics like politics or money with their mothers than family heart health history, despite hereditary risks [2] - Over half (56%) of women have never discussed heart health with their mothers or family members, and only one-third (35%) of those with a family history of heart disease have consulted their doctors about their heart risk [7][8] - 53% of women worry that their aging mothers may ignore symptoms of heart disease, yet only 44% have actually talked about heart health with them [7][8] Health Disparities - Women are 35% less likely than men to receive treatment for heart valve failure, and they account for 52% of deaths caused by high blood pressure [3] - Heart disease disproportionately affects women of color, with 43% of Hispanic women and 59% of Black women experiencing some form of cardiovascular disease [3] Campaign Objectives - The campaign encourages women to prioritize heart health by initiating conversations about family history and risk factors [4][13] - Medtronic aims to close the awareness gap regarding heart disease, particularly focusing on high blood pressure and heart valve failure [4][13] Company Commitment - Medtronic is dedicated to improving health outcomes for women through personalized, evidence-based healthcare solutions [5] - The company is actively promoting awareness and advocacy for women's heart health, as evidenced by their partnership with WomenHeart [12]

Financial Data and Key Metrics Changes - The company achieved $317 million in revenue for Q1 2025, reflecting a 9% increase on a constant currency basis and a 10% increase on an organic basis compared to the prior year [29][30] - Adjusted operating income rose to $65 million, up from $53 million in Q1 2024, resulting in an adjusted operating income margin of 20% compared to 18% in the prior year [31][32] - Adjusted diluted earnings per share increased to $0.88 from $0.73 in Q1 2024, driven by operating income growth despite a higher effective tax rate [32] Business Line Data and Key Metrics Changes - Cardiopulmonary segment revenue was $176 million, a 15% increase year-over-year, with heart-lung machine revenue growing approximately 30% [12][13] - Epilepsy revenue increased by 4%, with Europe and the rest of the world regions growing a combined 13% [15][17] - The company expects cardiopulmonary revenue to grow 9% to 10% for the full year 2025, up from a previous forecast of 7% to 8% [13][14] Market Data and Key Metrics Changes - The U.S. Epilepsy business experienced a 2% growth year-over-year, impacted by procedure deferrals due to a voluntary field safety notification [16][17] - The company anticipates low single-digit growth in the U.S. for epilepsy, while Europe and the rest of the world are expected to grow in the low double digits [17][19] Company Strategy and Development Direction - The company is focused on expanding its portfolio in areas of high unmet clinical need, particularly in neuromodulation and OSA [52][43] - The recent twelve-month data from the OSREY trial positions OSA as a significant long-term growth opportunity [8][43] - The company is investing in additional manufacturing capacity to support growth in cardiopulmonary and neuromodulation segments [14][39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to manage tariff impacts, estimating a negligible effect on adjusted operating income for the year [39][75] - The Italian Supreme Court's decision regarding the SNEA matter is seen as a positive development, allowing for greater capital allocation flexibility [36][43] - The company raised its overall organic growth outlook by 100 basis points to between 7% and 8% for 2025, reflecting strong first-quarter performance [19][40] Other Important Information - The company recorded a liability of $360 million related to the SNEA litigation, which is expected to retire a long-standing overhang [9][35] - Adjusted free cash flow for the quarter was $20 million, up from $11 million in the prior year, driven by stronger operating results [33][37] Q&A Session Summary Question: Can you help us understand the OSSPREY data in a competitive context? - Management highlighted the strength of the clinical data, noting that the trial included more severe patients and achieved a rapid therapeutic response [47][48] Question: What is the outlook for the HLM business and Essence rollout? - Management indicated strong demand for oxygenators and a significant increase in Essence placements, with regulatory approval in China being a major milestone [54][56] Question: Can you elaborate on the changes in the OUS Neuromodulation business? - Management noted improved commercial execution in Europe, with a focus on strengthening talent and customer segmentation [64][66] Question: What is the impact of tariffs on the company's guidance? - Management confirmed that the $5 million tariff impact is included in the guidance, with some pricing actions assumed to offset costs [70][75] Question: How does the company view its leverage ratio and capital allocation? - Management expressed confidence in a healthy leverage ratio and indicated a focus on investing in core businesses while remaining open to inorganic growth opportunities [88][89]

Core Viewpoint - HeartSciences Inc. has appointed three distinguished experts to its Scientific Advisory Board, enhancing its commitment to advancing AI-driven ECG technology for early heart disease detection [1][2]. Group 1: Appointments and Expertise - Dr. Girish Nadkarni, Dr. Joshua Lampert, and Dr. Akhil Vaid have been appointed to the Scientific Advisory Board, bringing extensive expertise in cardiology, AI, and data-driven healthcare [1][2]. - Dr. Nadkarni is a physician-scientist with significant contributions to AI and precision medicine, holding over 375 peer-reviewed publications and an h-index of 90, and has secured approximately $40 million in research funding [3][4]. - Dr. Lampert specializes in cardiac electrophysiology and machine learning, focusing on improving patient care through novel diagnostic tools and has received multiple awards for his contributions to patient care [5][6][8]. - Dr. Vaid is involved in applying machine learning in cardiology, with a focus on developing AI models for cardiac dysfunction detection and ensuring practical implementation of AI solutions in clinical settings [9][10][11]. Group 2: Company Overview and Objectives - HeartSciences is dedicated to enhancing the clinical utility of ECGs through innovative AI technology, aiming to improve cardiac screening, particularly in frontline clinical settings [12]. - The company possesses one of the largest libraries of AI-ECG algorithms and plans to offer these solutions via a cloud-based platform alongside a low-cost ECG hardware option [12]. - HeartSciences' first product candidate, the MyoVista® wavECG™, aims to provide diagnostic information related to cardiac dysfunction, traditionally available only through cardiac imaging, while also delivering conventional ECG data [12].

Company Participation in Investor Conferences - InMode Ltd. will participate in multiple investor conferences, including BNP 3rd Annual Aesthetics Day, Barclays West Coast Bus Trip, and Jefferies Global Healthcare Conference [1][2] - The BNP conference will feature a virtual fireside chat with CEO Moshe Mizrahy and CFO Yair Malca on May 19 at 11:00 am ET [1] - The Barclays West Coast Bus Trip will be an in-person event at InMode's North American headquarters in Irvine, CA on May 29, led by CFO Yair Malca [2] - The Jefferies Global Healthcare Conference will include an in-person fireside chat with CEO Moshe Mizrahy and CFO Yair Malca on June 4 at 3:10 pm ET in New York, NY [2] Company Overview - InMode is a leading global provider of innovative medical technologies, focusing on developing, manufacturing, and marketing devices that utilize novel radiofrequency (RF) technology [3] - The company aims to enable new surgical procedures and enhance existing treatments through its minimally invasive RF technologies [3] - InMode offers a comprehensive range of products across various medical categories, including plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology [3]

Core Insights - Daxor Corporation has launched a new Blood Volume Analysis (BVA) program at a healthcare center in the Tampa Bay region of Florida, enhancing fluid management and treatment outcomes for various medical conditions [1][3] - The facility will utilize Daxor's CLIA-certified ezBVA Lab, which provides blood volume analysis results within 24 hours [2] - Daxor's technology offers 98% accurate blood volume measurements, allowing for customized fluid management strategies, which can lead to improved patient outcomes and reduced healthcare costs [3] Company Overview - Daxor Corporation is recognized as the global leader in blood volume measurement technology, having developed the BVA-100, the only FDA-cleared diagnostic blood test for quantifying blood volume status [4] - Over 65,000 tests have been conducted at leading hospitals in the U.S., significantly improving performance metrics in various medical conditions, particularly in reducing mortality and readmissions for heart failure and critical care patients [4] - The company is engaged in ongoing trials for heart failure treatment with support from the NIH and is developing analyzers for combat casualty care in collaboration with the U.S. Department of Defense [4]